La ciencia es diversión


Vacunación vs infección natural. Un desafío en el diagnóstico de pacientes asintomáticos con COVID-19, cuando se desconoce el perfil de inmunidad.


Vaccine anti-COVID-19

Intense time-trial is developed to obtain the best vaccine anti-COVID-19. Two organisms, one from the UK (Oxford University) and another from China (CanSino Biologics) have achieved the most promising results so far. An adenovirus vector produces both vaccines (ChAdOx1 nCoV-19 and Adenovirus Type 5 Vector respectively) (from chimp and human), a non-replicating viral vector, which avoids all type of infection risks in humans. However, it is particularly noteworthy, that not only these two studies but most of the developing ones are using the SARS-CoV-2 spike (S) glycoprotein as the leading player of this time trial. Different formats have been used to prepare/release this protein, as a purified recombinant protein, as a non-replicating viral vector (as the two more advanced attempts described above) or as a messenger RNA (mRNA)–based vaccine.


Ver más

Vuelta a la normalidad a pesar del COVID-19



At this moment of the pandemic, a very critical point is to know if each of us is immunised and at the same time if is contagious or no. To know if people are immunised against COVID-19 is essential information to be able to undo this state of quarantine in which we are immersed. Only people who have been infected, but are already non-contagious, could return to their normal lives, allowing a progressive return to our previous routine. For this reason, it is essential to analyse the antibody load that each person presents. Therefore, the combined of an RT-PCR + a rapid serological test (for antibodies detection) is what should be imposed as a requirement to return to normality. First, a serological test could tell us if we have antibodies against the virus and only in the case we have specific antibodies in our blood, a confirmation by RT-PCR will be required to ensure that we are not infectious. A positive IgG with an already negative IgM, practically wouldn´t require confirmation by RT-PCR, but sometimes the virus or its proteins are maintained in blood for longer time. Thus, there exist different possibilities:


Ver más

Detección de la nueva enfermedad por coronavirus 2019 (COVID-19) mediante ensayos de serodiagnóstico rápido


On 31 December 2019, WHO was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan City, Hubei Province of China. The coronavirus disease (COVID-2019) was identified as the causative virus by Chinese authorities on 7 January. As part of WHO’s response to the outbreak, the R&D has been activated to accelerate diagnostics, vaccines and therapeutics for this novel coronavirus.

Coronavirus 2020
Figure 1. Coronavirus, 2020. Illustration by David S. Goodsell, RCSB Protein Data Bank doi: 10.2210/rcsb_pdb/goodsell-gallery-019


Ver más

¿Por qué elegir un antígeno recombinante?



Native antigens are extracted in their natural form from the corresponding source. Recombinant antigens are instead manufactured artificially. A common method of achieving this is to transform the heterologous expression system with a vector expressing the protein of interest, following which the expressed protein can be purified from the culture broth.


Ver más

Quimeras: antígenos de multi-epítopos



Figura 1. Quimeras

En Rekom Biotech nos hemos especializado en el diseño y la producción de antígenos de última generación: quimeras o antígenos compuestos por múltiples epítopos, que han mejorado sus propiedades antigénicas, como son la sensibilidad y la especificidad. Además, una de las principales ventajas de los antígenos quiméricos multiepítopos es evitar el uso de mezclas de proteínas en su ensayo para incrementar la sensibilidad del mismo. El número limitado de sitios de unión en la plataforma usada y las diferentes afinidades de las proteínas por estos sitios, podrían dar lugar a problemas en la reproducibilidad del ensayo.


Ver más